LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

LLY

1,085.48

+2.26%↑

JNJ

224.18

+0.75%↑

ABBV

218.1

+2.99%↑

UNH

384.54

+1.7%↑

MRK

116.03

+0.77%↑

Accueil・Liste d'Actions・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Ouvert

SecteurSoins de santé

4.81 1.69

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.7

Max

4.96

Chiffres clés
By Trading Economics
Revenu	36M -3.7M
Ventes	16M 66M
BPA	0.01
Marge bénéficiaire	-5.67
Employés	416
EBITDA	57M 15M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+19.37% upside

Dividendes
By Dow Jones
Prochains Résultats	10 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	225M 1.6B
Ouverture précédente	3.12
Clôture précédente	4.81

Sentiment de l'Actualité

By Acuity

50%

147 / 344 Classement par Healthcare

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2026, 20:30 UTC

Résultats

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 juin 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 juin 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 juin 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 juin 2026, 23:01 UTC

Acquisitions, Fusions, Rachats

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 juin 2026, 23:00 UTC

Acquisitions, Fusions, Rachats

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 juin 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 juin 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 juin 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 juin 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 juin 2026, 21:00 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 juin 2026, 20:46 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:38 UTC

Résultats

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 juin 2026, 20:21 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:12 UTC

Résultats

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Product Rev $594M

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 juin 2026, 20:05 UTC

Résultats

Palo Alto Networks 3Q Loss $177M >PANW

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

19.37% hausse

Prévisions sur 12 Mois

Moyen 5.67 USD 19.37%

Haut 6 USD

Bas 5 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

147 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.